ストックスクリーナーアプリを入手
35.20
0.34%
0.12
前日終値:
$35.08
開ける：
$35.34
24時間の取引高:
991.01K
Relative Volume:
0.91
時価総額：
$3.99B
収益：
$14.09M
当期純損益:
$-176.94M
株価収益率:
-16.37
EPS:
-2.15
ネットキャッシュフロー:
$-141.24M
1週間 パフォーマンス:
-0.20%
1か月 パフォーマンス:
-8.17%
6か月 パフォーマンス:
+85.65%
1年 パフォーマンス:
+35.59%
1日の値動き範囲:
$34.33
$35.70
1週間の範囲:
$33.91
$36.00
52週間の値動き範囲:
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
NAMS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
35.20 | 3.98B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 再開されました | H.C. Wainwright | Buy |
| 2025-08-25 | 開始されました | Wells Fargo | Overweight |
| 2025-07-17 | 開始されました | Goldman | Neutral |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2025-06-10 | 開始されました | Stifel | Buy |
| 2025-06-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-15 | 開始されました | TD Cowen | Buy |
| 2024-03-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-01-18 | 開始されました | Guggenheim | Buy |
| 2024-01-16 | 開始されました | Piper Sandler | Overweight |
| 2023-10-30 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Newamsterdam Pharma Company Nv (NAMS) 最新ニュース
Behavioral Patterns of NAMS and Institutional Flows - Stock Traders Daily
ID Info Business Services Limited Enters Reversal Setup in Weekly ChartsEconomic Indicators Overview & Target Triple-Digit Stock Opportunities - earlytimes.in
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 43,872 Shares - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 26,011 Shares of Stock - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 75,117 Shares - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $928,072.48 in Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 43,872 Shares of Stock - MarketBeat
Louise Frederika Kooij Sells 75,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
How (NAMSW) Movements Inform Risk Allocation Models - Stock Traders Daily
Is NewAmsterdam Pharma Company NV Equity Warrant a good long term investmentUtilities Sector Analysis & Identify Ideal Buy Points With Precision - earlytimes.in
EBITDA per share of NewAmsterdam Pharma Company N.V. – MUN:KH6 - TradingView — Track All Markets
Operating cash flow per share of NewAmsterdam Pharma Company N.V. – SWB:KH6 - TradingView — Track All Markets
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock outperform in 2025 bull marketMarket Growth Report & Short-Term Trading Alerts - Улправда
Analyst Downgrade: Will Lee Enterprises Incorporated LE70 stock keep raising dividendsJuly 2025 Big Picture & Precise Buy Zone Identification - moha.gov.vn
How NewAmsterdam Pharma Company N.V. Equity Warrant stock trades before earningsWeekly Investment Summary & Verified Swing Trading Watchlist - Улправда
Will NewAmsterdam Pharma Company N.V. stock deliver strong dividend growthEarnings Risk Summary & Detailed Earnings Play Strategies - Улправда
Can NewAmsterdam Pharma Company N.V. stock beat market expectations this quarterQuarterly Profit Report & Real-Time Volume Spike Alerts - Улправда
Aug Selloffs: Can NewAmsterdam Pharma Company N.V. stock beat market expectations this quarterMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
Is NewAmsterdam Pharma Company N.V. stock in correction or buying zone2025 Sector Review & Reliable Breakout Forecasts - Улправда
Is NewAmsterdam Pharma Company N.V. stock undervalued vs historical averagesJuly 2025 Technicals & Daily Stock Trend Reports - DonanımHaber
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts high net worth investorsMarket Performance Recap & Expert Curated Trade Ideas - DonanımHaber
Will NewAmsterdam Pharma Company N.V. stock outperform tech sector in 20252025 Earnings Surprises & Community Trade Idea Sharing - DonanımHaber
Why NewAmsterdam Pharma Company N.V. stock attracts global investorsOptions Play & Real-Time Sentiment Analysis - DonanımHaber
Is NewAmsterdam Pharma Company N.V. stock positioned for long term growthJuly 2025 Short Interest & High Return Trade Guides - Улправда
Will NewAmsterdam Pharma Company N.V. stock beat EPS estimatesPortfolio Gains Report & Real-Time Stock Entry Alerts - ulpravda.ru
NewAmsterdam Pharma (NASDAQ:NAMS) Given New $50.00 Price Target at Stifel Nicolaus - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Understanding Momentum Shifts in (NAMSW) - Stock Traders Daily
Is It Too Late To Consider NewAmsterdam Pharma After Its Strong 2025 Share Price Rally? - Yahoo Finance
Frazier Life Sciences Management L.P. Has $300.75 Million Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma Company N.V. $NAMS Holdings Lifted by Maverick Capital Ltd. - MarketBeat
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Price-Driven Insight from (NAMS) for Rule-Based Strategy - Stock Traders Daily
It is Poised to be a Bull Market for NewAmsterdam Pharma Company NV (NAMS) - setenews.com
Stempoint Capital LP Boosts Stake in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
SCYNEXIS (NASDAQ:SCYX) versus NewAmsterdam Pharma (NASDAQ:NAMS) Head to Head Analysis - Defense World
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Affinity Asset Advisors LLC - Defense World
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma’s REMBRANDT Trial: A Potential Game-Changer in Cardiovascular Treatment - MSN
NewAmsterdam Pharma Co (NAMS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
NAMS Analyst Forecasts - Quiver Quantitative
NewAmsterdam Pharma Company Grants Inducement Share Options to New Hires - Quiver Quantitative
Saturn V Capital Management LP Buys 104,342 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock gain from lower inflationMarket Growth Review & Free Technical Pattern Based Buy Signals - Newser
Is NewAmsterdam Pharma Company N.V. (KH6) stock attractive post correction2025 Volatility Report & Weekly High Conviction Trade Ideas - Newser
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock see PE expansionJuly 2025 Macro Moves & Entry and Exit Point Strategies - Newser
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownHere's Why - MarketBeat
NAMS: PREVAIL CVOT remains on track for 2026, with regulatory and commercial momentum building - TradingView
JPMorgan Chase & Co. Increases Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
How NewAmsterdam Pharma Company N.V. (KH6) stock trades after earningsWeekly Trade Analysis & Consistent Profit Trade Alerts - Newser
Newamsterdam Pharma Company Nv (NAMS) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):